Please login to the form below

Not currently logged in
Email:
Password:

Accenture and BMS launch Indian pharmacovigilance centre

Accenture and Bristol-Myers Squibb (BMS) have launched a center for pharmacovigilance in Chennai, India.

Accenture and Bristol-Myers Squibb (BMS) have launched a center for pharmacovigilance in Chennai, India.

The new centre will process and code of adverse event data and generate regulatory periodic and aggregate reports on safety, as well as physician medical review of adverse events. Over 140 Accenture employees will run the site.

Pharmacovigilance involves monitoring safety data, assessment and reporting of potential side effects of approved medicines.

According to Accenture and BMS, the jv is the first of its kind involving a collaboration for 'end-to-end' safety case processing.

The team is organised as a parallel process and extension of the BMS pharmacovigilance headquarters' operations, which will handle data and reports between the two companies.

Part of a multi-year R&D agreement signed in April 2007, the jv will aid BMS's in its efforts to expand R&D operations in India as part of the company's global strategy.

Dr John Balian, senior vice-president of global pharmacovigilance and epidemiology at BMS, said: "Working with Accenture, we will continue to access world-class talent to deliver on our regulatory obligations, while enhancing our focus on patient safety."

Eric Sandor, managing director of Accenture Pharmacovigilance Services, added: "Through a truly collaborative partnership with BMS, we have established an industry leading operation that is delivering substantial efficiency and improved flexibility for the company's pharmacovigilance organisation."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics